Daclatasvir

Janessa M. Smith, PharmD, BCPS
Daclatasvir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of chronic hepatitis C virus (HCV) genotype 1 or 3 infection, in combination with sofosbuvir (SOF).
    • Daclatasvir is indicated for treatment of HIV/HCV co-infected patients, in patients with compensated Child-Pugh Class A cirrhosis, decompensated Child-Pugh B or C cirrhosis and in patients that develop recurrent HCV post-transplant.

NON-FDA APPROVED USES

Treatment of HCV genotypes 2, 4.

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: August 1, 2016

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Daclatasvir ID - 540654 A1 - Smith,Janessa,PharmD, BCPS Y1 - 2016/08/01/ PB - Johns Hopkins ABX Guide UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540654/all/Daclatasvir ER -